---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-098546"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2025-10-10T23:59:59+00:00"
generated_at: "2026-05-17T04:06:07.359954+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CEO Robert Lisicki takes medical leave; COO Kim Davis appointed interim CEO effective Oct 10

## Summary
- CEO Robert Lisicki informed Zura Bio of a medical leave of absence starting October 10, 2025.
- Board appointed Kim Davis (COO, CLO, Corporate Secretary) as interim CEO effective October 10, 2025.
- Davis will serve as interim CEO in addition to her current duties as COO, CLO, and Corporate Secretary.
- No arrangement, transactions under Item 404(a), or family relationships disclosed related to appointment.

## SEC filing metadata
- accession: 0001104659-25-098546
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2025-10-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465925098546/0001104659-25-098546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465925098546/tm2528470d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-098546
- JSON: https://secwatch.observer/filing/0001104659-25-098546.json
- Plain text: https://secwatch.observer/filing/0001104659-25-098546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.